Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.30 USD
Change Today 0.00 / 0.00%
Volume 0.0
RBCL On Other Exchanges
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

rbc life sciences inc (RBCL) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/18/14 - $1.85
52 Week Low
03/6/15 - $0.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RBC LIFE SCIENCES INC (RBCL)

Related News

No related news articles were found.

rbc life sciences inc (RBCL) Related Businessweek News

No Related Businessweek News Found

rbc life sciences inc (RBCL) Details

RBC Life Sciences, Inc. manufactures, markets, and distributes nutritional supplements and personal care products in North America, Southeast Asia, and Australia. The company’s Nutritional Products segment offers nutritional supplements and personal care products, including herbs, vitamins, and minerals; and natural skin, hair, and body care products through a network of independent distributors and license arrangements. Its products include Stem-Kine, a dietary supplement; Microhydrin and Microhydrin Plus antioxidants; VitAloe, a blend of research-backed ingredients; OliViva, an antioxidant beverage to support immune and cardiovascular system; Organic Spirulina, a nutritious alga that provides range of nutrients and easily digested proteins; and NeuroBright to support brain function, and enhance energy and acuity. This segments products also comprise Colo-Vada Plus, a colon cleansing program; HydraCel to enhance the quality of drinking water; 24 Seven, a multivitamin/mineral supplement; Immune 360 to nourish and support the function of the immune system; and Aloe Gelee gel that provides the soothing and moisturizing. Its Medical Products segment offers wound care products for the treatment and healing of wounds, such as pressure ulcers, leg ulcers, cuts, burns, and abrasions. Its products include cleansers, dressings, hydrogels, collagen, calcium alginates, moisture barriers, antimicrobials, and a hydrogel wound dressing with Lidocaine. This segment also offers other wound care products designed to reduce destruction to skin and tissue caused by radiation; and to reduce pain and itching in the skin, and the internal mucosa caused by radiation reactions or reactions to various cancer medications. This segment sells its products under the MPM Medical brand to hospitals, nursing homes, clinics, and pharmacies through a network of medical/surgical supply dealers and pharmaceutical distributors. The company was founded in 1988 and is headquartered in Irving, Texas.

89 Employees
Last Reported Date: 03/31/15
Founded in 1988

rbc life sciences inc (RBCL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $280.0K
Founder and Chairman
Total Annual Compensation: $301.0K
Vice President of Operations
Total Annual Compensation: $138.0K
Compensation as of Fiscal Year 2014.

rbc life sciences inc (RBCL) Key Developments

RBC Life Sciences Inc. Announces Executive Changes

RBC Life Sciences Inc. announced that effective January 1, 2015, the board of directors of the company appointed Mr. Steven E. Brown, to serve as the company's chief executive officer and president. Prior to this appointment, Mr. Brown served as the company's president. In his capacity as CEO, Mr. Brown replaces Clinton H. Howard, whose resignation as CEO became effective January 1, 2015. Mr. Howard will continue to serve as the company's chairman of the board.

RBC Life Sciences Inc. Announces Executive Changes

Effective September 26, 2014, Mr. Kevin B. Young resigned his position as Vice President - Sales of RBC Life Sciences Inc. to participate in the Company's network marketing distribution system as an independent Associate. Mr. Young's duties will be assumed by Mr. Barton R. Dangerfield, Vice President - Marketing, until a replacement for Mr. Young is found. On September 26, 2014, the Board of Directors of the company appointed Ms. Daley L. Seeker, to serve as the company's Vice president - Finance, Chief Financial Officer, Treasurer and Secretary effective October 6, 2014. Ms. Seeker will join the Company on October 6, 2014 having held various positions, most recently as an Assurance Supervisor, in the Assurance Practice of McGladrey LLP, from 2011 to present. From 2010 until 2011, Ms. Seeker served as a Staff Auditor for the accounting firm of Gindler, Chappell, Morrison & Co., PC, and from 2008 to 2010, as an Audit Associate with McGladrey.

RBC Life Sciences Inc. Enters into Two-Year Exclusive Distributorship Agreement with Coral Club International, Inc

On August 22, 2014, RBC Life Sciences Inc. entered into a two-year exclusive distributorship agreement effective as of August 1, 2014 with Coral Club International, Inc. This Agreement replaces a ten-year exclusive distributorship agreement between the parties that automatically renewed for a one-year term following expiration of the initial term on July 1, 2014. CCI is the company's principal licensee and accounted for virtually all of the company's licensees' net sales in the six months ended June 30, 2014 and 2013, respectively. Pursuant to the Agreement, CCI's exclusive territory includes Russia and other countries located primarily in Europe and Central Asia, which represents an expansion of the territory set out in the Former Agreement. In consideration of the rights granted to CCI under the Agreement, CCI is required to purchase certain minimum amounts of products from the Company each year, which minimum amounts are consistent with the Former Agreement. Under the Former Agreement, CCI was required to pay the company a monthly royalty calculated as a percentage of its sales of the company's products. Under the Agreement, in lieu of a royalty, the prices at which products are sold to CCI were marked up as of the effective date of the Agreement to include the royalty so that no additional royalty will be due upon the sale of the company's products by CCI. To affect the transition of royalty calculations under the Former Agreement and the Agreement, the company will recognize on a one-time basis royalty revenue of approximately $476,000 in the third quarter of 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBCL:US $1.30 USD 0.00

RBCL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RBCL.
View Industry Companies

Industry Analysis


Industry Average

Valuation RBCL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.1x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RBC LIFE SCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at